Coronary Sinus Reducer Implantation for the Treatment of Chronic Refractory Angina.

A single Center Experience.

JACC VOL.11,n.8, 2018.


Giannini F. Baldetti L., Ponticelli F., Ruparelia N.,Mitomo S.,Latib A.,Montorfano M.,Jabbour R.J.,Aurelio A.,Ferri L.,Mangeri A.,Regazzoli D.,Ancona M.,Pagnesi M.,Faccini A,Chieffo A., Azzalini L.,Carlino M.,Colombo

(San Raffaele Hospital, Milan)

  • 50 pazienti trattati con Reducer tra marzo 2015 ad agosto 2016
  • Follow-up eseguito a 4 e 12 mesi
  • 100% Successo procedurale, nessun evento avverso relativo al device, né intraprocedurale né durante i follow-up
  • 40 pazienti (80%) hanno avuto un miglioramento di almeno 1 classe di angina (Canadian Cardiovascular Society class), 20 pazienti (40%) hanno avuto un miglioramento di almeno 2 classi (al follow-up di 4 mesi)
  • Tutti i questionari Seattle Angina Questionnaire hanno avuto un miglioramento di punteggio
  • Incremento del 6-minute walking test 388.6 ± 119.7 m vs. 287.0 ± 138.9 m (p = 0.004)
  • 32% hanno ridotto almeno 1 farmaco antiangina, 6% almeno 2.

PCR 2017

Booth M33 – Hall Maillot, Level 2.
“Interim data from an ongoing study show: pressure-controlled intermittent coronary sinus occlusion results in cardioprotection when given adjunct to PCI”
  1. Jain, Barts Heart Centre, London, UK
  • Abstract Euro17A-OP1053, presented during: Novel approaches for treatment of STEMI – Session comprising selected EuroPCR 2017 abstract submissions
  • TUESDAY, MAY 16, 2017, 3.30 PM, Room 252 A (Level 2)
Symposium sponsored by Miracor
TUESDAY, MAY 16, 2017, 5.15 PM – 6.45 PM, Room 241 (Level 2)
Targeting infarct size reduction to prevent heart failure”
Chairpersons: G.W. Stone, Columbia University, New York, USA
A. Zaman, Freeman Hospital, Newcastle, UK


The coronary sinus reducer: clinical evidence and technical aspects

Francesco GianniniAndrea AurelioRichard J. JabbourLuca FerriAntonio Colombo & Azeem Latib

Pages 47-58 | Received 26 Sep 2016, Accepted 07 Dec 2016, Accepted author version posted online: 09 Dec 2016, Published online: 15 Dec 2016


Introduction: Chronic refractory angina is often a disabling condition, predominantly due to severe obstructive coronary artery disease, that is inadequately controlled by optimal medical therapy and not amenable to further percutaneous or surgical revascularization. mortality rates associated with this condition are relatively low in clinically stable patients. however, it is associated with a high hospitalization rate and a reduction in both exercise capacity and quality of life. due to the paucity of available treatment options, there is an unmet need for new therapies for these patients and for a reduction in the associated economic healthcare burden.

Areas covered: This review is focusing on the clinical evidence and technical aspects of this new therapeutic modality in refractory angina patients unsuitable for revascularization.

Expert commentary: The Coronary Sinus Reducer (Neovasc Inc. Richmond B.C., Canada) is a new percutaneous device designed to achieve a controlled narrowing of the coronary sinus that may alleviate myocardial ischemia, possibly by redistributing blood from the less ischemic sub-epicardium to the more ischemic sub-endocardium, or by neoangiogenesis. Recently, a randomized, double-blind, multi-center clinical trial demonstrated a benefit in improving symptoms in 104 refractory angina patients, when compared to placebo.

KEYWORDS: Coronary sinus reducer implantationrefractory anginacoronary artery diseaseangina pectorismyocardial ischemia

Neovasc Receives Regulatory Approval to Initiate TIARA II CE Mark Study

RELEASE 28/11/2016 

Neovasc Inc. today announced it has received both regulatory and ethics committee approval to initiate the Tiara™ Transcatheter Mitral Valve Replacement Study (TIARA II) in Italy.   TIARA II is a 115 patient, non-randomized, prospective clinical study evaluating the safety and performance of the Tiara™ Transcatheter Mitral Valve with the Tiara™ Transapical Delivery System (Tiara™).

With these critical approvals now in place, it is expected that the first Italian TIARA II clinical study site will be initiated before year end, with first enrollment anticipated early in the new year.  Approvals in additional geographies are expected in the first quarter of 2017.

Catetere Navvus – Nuova Pubblicazione su EuroIntervention

Pubblicato sul numero online di Maggio 2015 di EuroIntervention (e ad Agosto lo sarà anche su formato cartaceo) un Technical Report relativo al microcatetere Navvus, originale ACIST MEDICAL SYSTEMS INC., dal titolo “Rapid exchange ultra-thin microcathter using fibre-optic sensing technology for measurement of intracoronary fractional flow reserve” redatto dai cardiologi del rinomato Thoraxcenter di Rotterdam.

Read more